Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL -November 02, 2023 at 10:38 am EDT
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 --...
Source: marketscreener.com